MycoMix®Immun K | Medicinal Mushrooms
Homeostasis of the gastrointestinal tract (GIT) depends upon a fine balance between the host and their microbes. The host's immune system is a key player here. For this reason, we have researched medicinal mushrooms for their immuno-modulating, anti-inflammatory and anti-viral/bacterial/parasitic properties.
MycoMix®Immun K contains over one-hundred different biologically active compounds, and up to ten times as many medicinal substances as does one medicinal mushroom species alone.
Research in this area is burgeoning, so we've collated a short review of each mushroom species in the mix.
H. erinaceus contains bioactive components with described anti-inflammatory and anti-bacterial activity, cytotoxic effect on cancer cells and compounds that stimulate the synthesis of nerve growth factor (NGF), sustain the myelination process and improve cognitive functions (1). Hence, it has been referred to as 'nature’s nutrient for the neurons' (2).
A double-blind, parallel-group, placebo-controlled trial showed significantly increased scores on the cognitive function scale, compared with placebo (p<0.001) in women diagnosed with mild cognitive impairment at week 8, 12 and 16 of supplementation (3).
In an ethanol-induced ulcer rodent study, pre-treatment with H. erinaceus extract increased mucus production in a dose-dependent manner up to 1.49-fold higher (p<0.05) than that of the ulcer control group, and significantly decreased the ulcer (p<0.05) in a dose-dependent manner when compared to ulcer control. The ulcer area was also significantly (p<0.05) reduced (4).
A recent (un-published) study provides early evidence for H. erinaceus as an anti-inflammatory agent in gastrointestinal disease. 56 subjects with elevated calprotectin (>50ug/g) and gastrointestinal discomfort were supplemented over 2 months (2g/d). After 2 months, an average improvement of faecal calprotectin scores was measured in the following disease groups: Chron's 74.8%; Ulcerative Colitis 74.5% and IBD 75.8%, together with a reduction in symptoms (5).
A diverse array of circa 400 biologically active compounds have been identified in G. lucidum, including polysaccharides, terpenes, steroids, phenols, nucleosides, proteins and peptidoglycans. The most pharmacologically important are polysaccharides and triterpenes, with more than 200 and 130 found, respectively (6).
Triterpenoids have been reported to posses anti-inflammatory hepato-protective, anti-hypertensive, hypocholesterolemic, anti-histaminic effects, anti-tumor and anti-engiogenic activity (6).
Polysaccharides, especially β-D-glucans, have been shown to possess anti-tumor effects through immuno-modulation and anti-angiogenesis. In addition, polysaccharides have a protective effect against free radicals and reduce cell damage caused by mutagens (7).
Min et al. reported that ganoderiol F, ganodermanondiol, ganodermanontriol from spores of G. lucidum exhibited strong anti-complement activity, through which these substances can affect the humoral immune system in the host defence (8).
G. lucidum has been proposed as a promising antibiotic and anti-viral, since it showed anti-bacterial activity against various bacteria, and inhibitory effect on HIV-1, herpes simplex virus type 1 and 2, hepatitis B, and vesicular stomatitis virus (9).
It has been used as a sedative, to relieve insomnia and anxiety, and is traditionally recommended for mental stabilisation (2).
Recognised in particular for its anti-tumour and immuno-stimulatory activity, however, studies have also shown its anti-inﬂammatory and anti-allergic properties, as well as hepato-protective and anti-viral activity (6). The mushroom has traditionally also been used to reduce physical and emotional stress, and in a variety of diseases, including hepatitis, dermatitis, osteoporosis, peptic ulcers, as well as digestive and cardiovascular disorders (10).
Clinical studies have shown Cordyceps to reduce scores of fatigue, increase vitality and energy by enhancing the cellular immune response and modulating the immune system (11). Cordyceps have also been shown to inhibit vital replication (2, 11).
The therapeutic effects of G. frondosa are predominantly attributed to its unique β-glucan polysaccharide. The mushroom exerts an anti-tumour effect primarily by stimulating the immune system through the activation of immune cells and increased production of cytokines (6). Moreover, it has anti-oxidant, hepato-protective, anti-viral and anti-microbial properties (12).
In traditional Chinese and Japanese medicine, Poria is used as a diuretic, sedative, and tonic for overall health and vitality (6). The fungus also exhibited activity against parasites, including Trypanosoma cruzi and several nematode species (13).
Research has focused primarily on the anti-tumour properties of the two pharmacologically active polysaccharide-protein complexes or proteoglycans, called PSK (Polysaccharide-K or Krestin) and PSP (Poly-saccharide-Peptide), which have been evaluated in large-scale clinical trials. The compounds have been shown to be effective immunotherapeutics in cancer management, especially when combined with conventional treatment, without exhibiting toxicity or serious adverse side effects (14).
PSK is the first approved medicine derived from a mushroom and is one of the most widely accepted for the treatment of certain types of cancer, particularly in Japan. In numerous clinical studies, PSK has shown impressive results in patients with gastric, as well as colorectal, oesophageal, nasopharyngeal, uterine, lung and breast cancer, and leukaemia. In conjunction with conventional treatment, PSK significantly extended survival, enhanced the immune system by increasing immune cell count and reduced side effects of radiation and chemotherapy. In addition, PSK showed anti-oxidant properties and potentiated the immune response in 70–97% of patients with gastric, oesophageal, lung, ovarian and endometrial cancer (14).
Lentinan – a polysaccharide from Lentinula edodes - has been approved in Japan as an adjuvant in the treatment of gastric cancer (6). It also displays activity against viral, bacterial, fungal and parasitic infections, such as candidiasis, common cold and inﬂuenza (2).
1. Thongbai, B., Rapior, S., Hyde, K.. et al. (2015). Hericium erinaceus, an amazing medicinal mushroom. Mycol Progress 14:91
2. Powell M. 2010. Medicinal mushrooms: A clinical guide. East Sussex, Mycology Press
3. Mori, K., Inatomi S., Ouchi, K., et al. (2009). Improving Effects of the Mushroom Yamabushitake (Hericium erinaceus) on Mild Cognitive Impairment: A Double-blind Placebo-controlled Clinical Trial. Phytother. Res. 23, 367:372
4. Wong, J.Y., Abdulla, M. A., Raman, J., et al. (2013). Gastroprotective Effects of Lion's Mane Mushroom Hericium erinaceus (Bull.:Fr.) Pers. (Aphyllophoromycetideae) Extract against Ethanol-Induced Ulcer in Rats. Evidence-based Complementary and Alternative Medicine 2013:492976
5. Cazzavillan, S., & Gregori, A (2018) First report on management of fecal calprotectin using Hericium erinaceus. [pre-published]
6. Pohleven, J., Korosec, T., Gregori, A. (2016). Medicinal mushrooms. Available from: https://www.researchgate.net/publication/310797100_Medicinal_mushrooms
7. Boh, B., Berovic, M., Zhang, J., et al (2007). Ganoderma lucidum and its pharmaceutically active compounds. Biotech. An. Rev. 13(7):265:301
8. Min, B.S., Gao, J.J., Hattori, M., et al. (2001). Anticomplement activity of triterpenoids from the spores of Ganoderma lucidum. Planta. Med. 67:811–814
9. Wachtel-Galor, S., Yuen, J., Buswell, J. A. et al. 2011. Ganoderma lucidum (lingzhi or reishi) a medicinal mushroom. In: Herbal medicine: Biomolecular and clinical aspects. 2nd edition. Boca Raton, FL, CRC Press: 175–199
10. Firenzuoli, F., Gori, L., Lombardo, G. 2008. The medicinal mushroom Agaricus blazei Murrill: Review of literature and pharmaco-toxicological problems. Evidence-Based Complementary and Alternative Medicine. 5(1):3:15
11. Lin, B.Q., Li, S.P. 2011. Cordyceps as an herbal drug. In: Herbal medicine: Biomolecular and clinical aspects. 2nd edition. Boca Raton, FL, CRC Press: 73–105
12. Boh B., Berovič M. 2007. Grifola frondosa (Dicks.: Fr.) S.F. Gray (maitake mushroom): Medicinal properties, active compounds, and biotechnological cultivation. International Journal of Medicinal Mushrooms, 9, 2: 89–108
13. Ríos, J. L. 2011. Chemical constituents and pharmacological properties of Poria cocos. Planta Medica, 77, 7: 681–691
14. Kidd, P. M. 2000. The use of mushroom glucans and proteoglycans in cancer treatment. Alternative Medicine Review, 5, 1: 4–27